134. E. Bilensoy, Trends of Drug Development and Research in Europe, 7th BBBB International Conference on Pharmaceutical Sciences, 5-7 October 2017, Balatonfüred (Invited lecture)
133. E. Bilensoy, Cholesterol targeted amphiphilic cyclodextrin nanomedicines, ADRITELF Summer School on nanomedicines, 25-28 September 2017, Cagliari (Invited lecture)
132. Varan C, Şen M, Sandler N, Aktaş Y, Bilensoy E. Printing and characterization of antiviral and anticancer drug loaded film formulation by using inkjet printer, 7th BBBB International Conference on Pharmaceutical Sciences, Balatonfüred, 2017
131. Daşkın, D., Erdoğar, N., İskit, A.B., Bilensoy, E., Novel Anionic and Cationic Polymeric Nanocapsules for Oral Delivery of Docetaxel: Preparation, In Vitro and In Vivo Evaluation, 7th BBBB International Conference on Pharmaceutical Sciences, 5-7 October 2017, Balatonfüred, Hungary. (Oral presentation)
130. Erdoğar N., Esendağlı G., Nielsen T.T., Esendağlı-Yılmaz G., Sargon M.F., Eroğlu H., Öner L., Bilensoy, E., In vitro and In Vivo Evaluation of Tumor-Targeted Nanoparticles for Paclitaxel Delivery with Folate-conjugated Amphiphilic Cyclodextrin Derivatives, 5th European Cyclodextrin Conference (EUROCD 2017), 3-6 October 2017, Lisbon, Portugal. (Oral Presentation)
129. Varan C, Sandler N, Bilensoy E. Anticancer and Antiviral Drug Printed Bioadhesive Film for Cervical Cancer:Ink Formulation Development by using Cyclodextrin Derivatives, 5th European Conference on Cyclodextrin, Lisbon, 2017
128. Varan G, Borchard G, Bilensoy E. Evaluation of Cellular Interaction and Tumoral Penetration Properties of Amphiphilic Cyclodextrin Nanoparticles on 3D Tumor Model, 5th European Conference on Cyclodextrin, Lisbon, 2017
127. Varan C, Şen M, Sandler N, Bilensoy E. Preparation and Characterization of Antiviral and Anticancer Drug Printed Film Formulations fort he treatment of Cervical Cancer, Innovation in Medicine Meetings III Congress, Gaziantep, 2017
126. Varan G, Öncül S, Ercan A, Benito J.M, Mellet C.O, Bilensoy E. Evaluation of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles for Cancer Therapy, Innovation in Medicine Meetings III Congress, Gaziantep, 2017
125. Erdoğar N., Esendağlı G., Nielsen T.T., Esendağlı-Yılmaz G., Sargon M.F., Öner L., Bilensoy, E., Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer, Innovation in Medicine Summit-3, 11-13 Mayıs 2017, Gaziantep, Türkiye. (Sözlü sunum)
124. E. Bilensoy, Nanomedicines: Pre-clinical and clinical evaluation, Market status and R&D, Sanko Innovation in Medicine Summit III, 11-12 May 2017, Gaziantep, (Invited lecture)
123. E. Bilensoy, Cholesterol Targeted Nanoparticles for Cancer Therapy, DYO Forum, 11-12 February 2017, Athens (Invited lectue)
122. E. Bilensoy, Nanomedicines and Nanosimilars: Regulatory Status, Market and R&D, Turkish Congress of Pharmacy, 21-24 December 2016, İstanbul (Invited lecture)
121. Y, Karabey Akyürek, E. Bilensoy, H. Eroğlu, AG Gürcan, O. Gürcan, S. Yabanoğlu Çiftçi, MF Sargon, L. Öner, “Development of neuroprptective drug loaded nanoparticulate drug delivery system for the treatment of acute spinal cord injuries, IPTS 2016, 18-21 September 2016, Antalya
120. N. Erdoğar, G. Esendağlı, TT Nielsen, B. Erdoğdu, M. Şen, H. Eroğlu, L. Öner, E. Bilensoy, Tumor specific delivery and In Vitro-In Vivo Evaluaton of Novel Paclitaxel Loaded Folate Conjugated Amphiphilic Cyclodextrin Nanoparticles, IPTS 2016, 18-21 September 2016, Antalya
119. E. Bilensoy, EUFEPS, advancing sciences for better medicines and health, 29th Romanian national Congress of Pharmacy, 28 September-1 October 2016, Bucharest (Invited lecture)
118. E. Bilensoy, EUFEPS for the Voice of Pharmaceutical Scientists, CESPT 2016, 22-24 September 2016, Belgrade (Invited lecture)
117. E. Bilensoy, Nanomedicines and Nanosimilars: Regulatory and Market Landscape, Drug Solubility, Formulation and Bioavailability Summit, 30-31 May 2016, Barcelona (2016) (invited lecture)
116. E. Bilensoy, Nanosimilars: Development and regulation of Generic Nanomedicines, DUPHAT 2016, 15-15 March 2016, Dubai (Invited lecture)
115. E. Bilensoy, Tumor targeted nanoparticles: opportunities and challenges, DUPHAT 2016, 15-15 March 2016, Dubai (Invited lecture)
114. E. Bilensoy, Nanomedicines and nanosimilars: Regulatory and Market Landscape, ICAB 2015 International Conference on Advances in the Area of Bioequivalence, Budapest, 14 November 2015 (Invited lecture)
113. E Bilensoy, Cyclodextrin nanomedicines. Potential and challenges in the pharma industry, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (Invited lecture)
112. N Erdoğar, L Öner, G Esendağlı, TT Nielsen, E Bilensoy, Optimization by 32 Factorial Design of Tumor-Targeted Nanoparticles for Paclitaxel Delivery with Folate-conjugated Amphiphilic Cyclodextrin, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (Oral presentation)
111. C Varan, N Sandler, Y Aktaş, E Bilensoy, Nanoparticulate Cidofovir and Paclitaxel-Cyclodextrin Complex Combination in Ink Jet Printed Adhesive Film for HPV Infection, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (Oral presentation)
110. Işık G, Öncül S, Ercan A, Benito JM, Ortiz Mellet C, Bilensoy E, Determination of apoptotic effect of anionic and polycationic amphiphilic cyclodextrin nanoparticles in MCF-7 human breast carcinoma cells, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (oral presentation)
109. Conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biowaivers, 15-17 September 2015, Amman
108. C Varan, N Sandler, Y Aktaş, E Bilensoy, Preparation and characterization of Cidofovir and Paclitaxel loaded bioadhesive film for the treatment of HPV-induced cervical cancer by printing technology, EUFEPS Annual Meeting 2015, 15-17 June 2015, Geneva
107. G Işık, S Öncül, JM Benito, C Ortiz Mellet, E Bilensoy, Determination of apoptotic effect of anionic and polycationic amphiphilic cyclodextrin nanoparticles in MCF-7 human breast carcinoma cells, EUFEPS Annual Meeting 2015, 15-17 June 2015, Geneva
106. Bilensoy, E., Tumor targeted nanoparticles: Challenges and Opportunities, Personalized Medicine and What Will it Bring in the Future EU Twinnet Project Meeting, Ankara, 21-28 February, 2015 (Invited lecture)
105. Bilensoy, E., Tumor targeted nanoparticles: opportunities and challenges, Boğaziçi University Depertment of Chemistry Seminars, 3 December 2014, İstanbul (Invited lecture)
104. Bilensoy, E., Nanoparticles for loacal or systemic chemotherapy: Improvement of drug safety and efficacy, 1st International Symposium from Drug Discovery to Delivery, 13-15 November 2014, Athens (Invited lecture)
103. Akyürek, Y., Nemutlu, E., Bilensoy, E., Öner, L., An improved and validated HPLC method for the determination of methylprednisolone sodium succinate in pharmaceutical preparations, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
102. Ünal, H., Quaglia, F., Bilensoy, E., Comparative in vitro and in vivo evaluation of camptothecin loaded oral nanocapsules, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
101. Işık, G., Ercan, A., Benito, JM, Mellet CO, Bilensoy, E., Polycationic cyclodextrin nanoparticles for the delivery of paclitaxel to breast tumors, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
100. Varan, C., Bilensoy, E., Docetaxel loaded hydroxypropyl-B-cyclodextrin polycaprolactone nanoparticles: formulation development and in vitro characterization, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
99. Rahic, O., Vranic, E., Bilensoy, E., The influence of microcrystalline cellulose-lactose ratio on drug release performence of pellets prepared by extrusion/spheronization, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
98. Vranic, E, Rahic, O., Bilensoy, E., Rheological characterization of microcrystalline cellulose-based wet masses prior to extrusion, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya
97. Bilensoy E., Cationic coated nanoparticles for intravenous or oral administration in cancer chemotherapy, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya (Invited lecture)
96. Erdoğar, N., Öner, L., Esendağlı, G., Nielsen, TT, Bilensoy, E., Optimization of tumor targeted nanoparticles for paclitaxel delivery with folate-PEG conjugated amphiphilic cyclodextrins, GPEN 2014, 27-29 August 2014, Helsinki
95. Bilensoy, E., Cationic hybrid nanoparticles as delivery systems for anticancer drugs via oral, mucosal or pareneral routes, CRS Nordic Chapter Meeting, 26-27 August 2014, Helsinki (Invited lecture)
94. Ünal, H., Quaglia, F., Bilensoy, E., Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation, NANOTR-10 10th Nanoscience and Nanotechnology Conference, 17-21 July 2014, İstanbul (Oral presentation)
93. Bilensoy, E., Effect of surface modification and core-shell strategy on anticancer drug delivery with CD nanoparticles, 17th International Cyclodextrin Symposium ICS17, 29-31 May, 2014, Saarbrücken (Oral presentation)
92. Bilensoy, E., “Impact of positively charged nanoparticles on anticancer drug delivery” University of Naples Federico II, 30 January 2014, Naples (Invited lecture)
91. Ünal H, Bilensoy, E., Oral cyclodextrin nanocapsules for camptothecin delivery: formulation development and in vitro evaluation, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
90. Varan C, Bilensoy, E., Development of docetaxel loaded hydroxypropyl-β-cyclodextrin polycaprolactone nanoparticles for the treatment of solid tumors, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
89. Erdoğar N, Şen, M, Bilensoy E, Improvement of oral bioavailability of anticancer drug tamoxifen through complexation with water soluble cyclodextrins, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
88. Çelen N, Öztürk K, Bilensoy E, Çalış S, Enhanced solubility of cefixime, a poorly soluble drug, with using hydroxypropyl β-cyclodextrin, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
87. Vranic E., Grzic D, Planinsek O, Srcic, S, Bilensoy, E., Release behavior of microencapsulated ternary celecoxib/β-cyclodextrin/alginate complex, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
86. Grzic D, Vranic E, Planinsek O, Srcic, S, Bilensoy E., Influence of hydrophilic plymers on the improvement of celecoxib-β-cyclodextrin complex formation efficiency, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya
85. Işık, G., Ercan, A., Benito, JM, Ortiz Mellet C, Bilensoy, E., Polycationic amphiphilic cyclodextrin nanoparticles for the delivery of paclitaxel to breast tumors, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya (oral presentation)
84. Bilensoy, E., Cyclodextrin based nanomedicines, 2nd International Summer School on Cyclodextrins, Giardini Naxos, 7-8 May, 2013 (Invited lecture)
83. Bilensoy, E., Linden HH, EUFEPS for Pharmaceutical Sciences, education, training, Collaboration and policy, 16th EAFP Symposium, 17 May 2013, Ankara (Oral presentation)
82. Bilensoy, E., Amphiphilic cyclodextrin nanoparticles in tumor targeting, 4th International CD.TEC., 8-9 May, 2013, Giardini Naxos, Italy (Invited lecture)
81. Bilensoy, E., Cationic nanoparticles for cancer chemotherapy, Select Nanomedicine 2013, 11-12 April 2013, Barcelona (Invited lecture)
80. Bilensoy, E., Pharmaceutical Carrying Systems in Cancer Treatment, Shrink the World-9, 17-23 February 2013, Ankara (Invited lecture)
78. Bilensoy, E., Cationic core-shell nanoparticles for mucosal delivery of anticancer drugs, 17th Rencontre Pharmapeptides Nanomedicine, 16 November 2012, Archamps (Invited lecture)
77. Erdoğar N, Eroğlu H., İskit AB, Sargon MF, Mungan NA, Bilensoy E., In vivo evaluation of cationic nanoparticles designed for intravesicsl therapy of bladder tumors, 9th Central European Sympoium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik
76. Ünal, H., Bilensoy, E., Preparation and characterization of oral PCL nanocapsules loaded with anticancer drug exemestane, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik
75. Varan, C., Bilensoy, E., Docetaxel loaded cationic core-shell polycaprolactone nanoparticles designed for rat glioma model, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik
74. Işık, G., Benito, JM, Ortiz Mellet C., Bilensoy, E., Design of paclitaxel loaded amphiphilic cyclodextrin nanospheres for breast cancer therapy, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik
73. Bilensoy, E., Cationic core-shell nanoparticles for intravesical chemotherapy and immunotherapy, CESPT 2012, 20-22 September 2012, Dubrovnik (oral presentation)
72. Varan, C., Bilensoy, E., Docetaxel loaded core-shell polycaprolactone nanoparticles: formulation development and characterization, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Antalya
71. Ünal, H., Bilensoy, E, Formulation and in vitro characterization of oral polycaprolactone nanocapsules in breast cancer therapy, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Ankara
70. Işık, G., Benito, JM, Ortiz Mellet, C., Bilensoy, E., Design of paclitaxel loaded polycationic and anionic amphiphilic cyclodextrin nanospheres for breast cancer therapy, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Antalya
69. Işık, G., Benito, J, Mellet CO, Bilensoy, E., Anionic and cationic cyclodextrin nanospheres for breast cancer therapy, 8th Nanoscience and Nanotechnolog Congress NANOTR VIII, 25-29 June 2012, Ankara
68. Ünal, H., Bilensoy, E., Chitosan coated oral polycaprolactone nanocapsules for cancer therapy: effect of formulation parameters on particle size, 8th Nanoscience and Nanotechnolog Congress NANOTR VIII, 25-29 June 2012, Ankara
67. Varan, C., Bilensoy, E., Polycaprolactone nanoparticles for rat glioma model: influence of formulation parameters and particle size and zeta potential, 8th Nanoscience and Nanotechnolog Congress NANOTR VIII, 25-29 June 2012, Ankara
66. Varan, C., Bilensoy, E., Core-shell polycaprolactone nanoparticles for rat glioma model: formulation development and characterization, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik
65. Işık, G., Benito, JM., Ortiz Mellet, C., Bilensoy, E., Formulation and characterization of anionic and cationic cyclodextrin nanospheres designed for tumor therapy, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik
64. Ünal, H., Bilensoy, E., Formulation and in vitro characterization of oral polycaprolactone nanocapsules intended for brest cancer therapy, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik
63. Bilensoy, E., Anionic and cationic cyclodextrin nanoparticles for cancer therapy, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik (invited lecture)
62. Grizic, D., Vranic, E., Bilensoy, E., Influence of layered double hydroxides on release profile of ıbuprofen from alginate microspheres, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya
61. Vranic, E., Grizic, D., Bilensoy, E., Microencapsulation of layered double hydroxide-ibuprofen complex: formulation and release evaluation, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya
60. Bilensoy, E., Bioavailability/Bioequivalence Requirements and Challenging Issues for Modified Release Oral Dosage Forms: Study Design, Food Effect and Dos Dumping due to Alcohol, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya (invited lecture)
59. Bilensoy, E., Design and In Vitro-In Vivo testing of cationic nanocarriers loaded with chemo- or immunotherapeutics for treatment of bladder cancer, 3rd PharmSciFair, 13-17 June 2011, Prag (invited lecture)
58. Bilensoy, E., Impact of positively charged nanoparticles on efective chemotherapy of bladder tumors, 15th International Pharmaceutical Technology Sympoum IPTS-2010, 13-15 September 2010, Antalya (invited lecture)
57. Hıncal, A.A., Eroğlu, H., Bilensoy, E., Safety and efficacy of amphiphilic cyclodextrins for drug delivery, ISSX 9th International Meeting, 4-7 September 2010, İstanbul (invited lecture)
56. Orhan E., Yüzbaşıoğlu, M., Erol, S., Erdoğan, B., Kuruüzüm-Uz, A., Bilensoy, E., Erdoğar, N., Bilgili, B., Duman H., Demirezer, L.Ö., The effect of Arnebia purpurea on random pattern ski,n flap survival in rat, Trends in Natural Products Research, 12-14 April 2010, Leicester
55. Erdoğar, N., Mungan, N.A., Bilensoy, E., Preparation and characterization of cationic nanoparticles loaded with mitomycin c by double emulsion and ionotrpoic gelation techniques, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 255-57
54. Çırpanlı, Y., Bilensoy, E., Doğan, A.L., Çalış, S., Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 273-276
53. Yavuz, B., Sarısözen, C., Vural, İ., Bilensoy, E., Şumnu, M., An alternative cyclodextrin-based formulation for oral anticancer drug exemestane: in vitro and cell culture studies, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 269-272 (2009)
52. Yerlikaya F, Launay M, Gegu C, Leturgez T, Bilensoy E, Çalış S, Çapan Y, Analytical method development and validation of tamoxifen citrate using normal phase high performance liquid chromatography, 3rd BBBB International Conference on Pharmacuetical Sciences, 26-28 October 2009, Antalya
51. Bilensoy, E., Moroy, P., Çırpanlı, Y., Bilensoy, T., Çalış, S, Mollamahmutoğlu, L., Placebo-controlled clinical trial of thermosensitive gel loaded with 5-FU:cyclodextrin complex for treatment of HPV-induced genital lesions, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg
50. Bilensoy, E., Effective delivery of anticancer agents with amphiphilic ß-cyclodextrin nanoparticles, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg (oral presentation)
49. Yavuz, B., Bilensoy, E., Şumnu, M, Cyclodextrin complexation increases the dissolution rate and permeation of oral anticancer drug exemestane, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg (oral presentation)
48. Bilensoy, E., Amphiphilic cyclodextrin nanoparticles for cancer therapy, Workshop on Cyclodextrins in Pharmaceutical Technology, 14 July 2009, Perugia (invited lecture)
47. Karabey, Y., Bilensoy, E., Öner, L., Effect of poly-L-lysine coating on drug loading for methyl prednisolone sodium succinate nanoparticles, 2nd PharmSciFair, 8-12 June 2009, Nice
46. Yavuz, B., Bilensoy, E., Şumnu, M., Inclusion complexes of oral chemotherapeutic exemestane with cyclodextrins: characterization and phase solubility studies, 2nd PharmSciFair 2009, 8-12 June 2009, Nice
45. Bilensoy, E., Amphiphilic beta-cyclodextrin nanoparticles for cancer therapy, 2nd PharmSciFair 2009, 8-12 June 2009, Nice (invited lecture)
44. Bilensoy, E., Safe and effective delivery of paclitaxel through amphiphilic ß-cycloxdextrin nanoparticles, EHRLICH II-2nd World Conference on Magic Bullets, October 2-4, 2008, Nurnberg (oral presentation)
43. Cırpanlı, Y., Bilensoy, E., Passirani, C., Çalış, S., Benoit, J.P., Evaluation of camptpthecin loaded nanoparticles for malignant gliomas, GPEN 2008, 9-12 September, 2008, Leuven
42. Çırpanlı, Y., Bilensoy, E., Çakmak, A., Çalış, S., Formulation and in vitro evaluation of triclosan coated grafts, 7th Central European Symposium on Pharmaceutical Technology and Biodelivery Systems, 18-20 September 2008, Ljubljana
41. Yavuz, B., Bilensoy, E., Şumnu, M., Analytical method validation for oral anticancer drug exemestane, 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey
40. Sarısözen, C., Esendağlı, G., Aktaş, Y., Doğan, A.L., Mungan, N.A., Bilensoy, E., Cellular uptake and anticancer efficacy of cationic nanoparticles loaded with Mitomycin C for bladder cancer, 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey
39. Uzunovic, A., Vranic, E., Bilensoy, E., Assessment of permeation of cafuroxime axetil from tablets by in vitro passive absorption model, 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey
38. Bilensoy, E., Applications of in vitro dissolution profiles to drug registration and BE studies, 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey (invited lecture)
37. Çırpanlı, Y., Bilensoy, E., Çalış, S., Formulation and in vitro evaluation of camptothecin loaded poly-e-caprolactone nanoparticles, 6th World Meeting on Pharmaceutics, Biopharmacedutics and Pharmaceutical Technology, Barcelona, 7-10 April 2008
36. Sarısözen, C. Doğan, A.L., Esendağlı, G., Aktaş, Y., Mungan, N.A., Bilensoy, E., Bioadhesive Chitosan Nanoparticles for effective delivery of Mitomycin C in superficial bladder cancer therapy, 8th International Conference of the European Chitin Society EUCHIS’07, 8-11 September 2007, Antalya (oral presentation)
35. Sarısözen, C., Aktaş, Y., Mungan, N.A., Bilensoy, E., Bioadhesive coated poly-epsilon-caprolactone Nanoparticles loaded with Mitomycvin C for the treatment of superficial bladder tumors, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007
34. Rouf, M.A., Bilensoy, E., Vural, İ., Hıncal, A.A., Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007
33. Rouf, M.A., Bilensoy, E., Vural, İ., Hıncal, A.A., Determination of stability of rapamycin following exposure to different conditions, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007
32. Bilensoy, E., Tumor-targeted Nanoparticles for cancer therapy, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007 (oral presentation)
31. Çırpanlı, Y., Bilensoy, E., Çalış, S., Hıncal, A.A., Stabilization of camptothecin in PLGA Nanoparticles, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007 (oral presentation)
30. Bilensoy, E., Tumor-targeted nanoparticles for cancer therapy, 31st FEBS Congress-Molecules in Health and Disease, İstanbul, 2006 (invited lecture)
29. Hıncal, AA ve E. Bilensoy, Formulation of poorly water soluble drugs with amphiphilic cyclodextrins, 18th Helsinki Drug Research 2006, Helsinki, 2006 (invited lecture)
28. Hincal, AA ve E. Bilensoy, Importance of the Design of Pharmaceutical Formulation from the Point of Bioequivalence, Proceedings of the First Bosnia and Herzegovinias Congress on Pharmacy, p.50-51, Sarajevo, 2006 (invited lecture)
27. Gürkaynak, O., E. Bilensoy, A.L. Doğan, A.A. Hıncal, Paclitaxel Loaded Amphiphilic β-cyclodextrin Nanoparticles: Hemolysis, Cytotoxicity Upon Injection and Anticancer Efficacy, 33rd Annual Meeting and exposition of the Controlled Release Society, Vienna, 200629. Çırpanlı, Y., E. Bilensoy, 29. M. Şen, S. Çalış, A.A. Hıncal, Camptothecin Inclusion Complexes with Natural and Modified β-Cyclodextrins, 33rd Annual Meeting and exposition of the Controlled Release Society, Vienna, 2006
26. Gürkaynak, O., E. Bilensoy, M. Duman, B. Salih, ve A.A. Hıncal, Paclitaxel Complexation to 6-O-CAPRO-β-CD and its in stability in a nanoparticulate system, 13th International Symposium on Cyclodextrins, Torino, 2006 (oral presentation)
25. Bilensoy, E., M. A. Rouf, İ. Vural, A.A. Hıncal, Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to β-cyclodextrin, Proceedings of 9th European Symposium on Controlled Drug Delivery, Nordwijk aan Zee, 2006
24. Gürkaynak, O., E. Memişoğlu-Bilensoy, İ. Vural, M. Şen, M. Duman, A.A. Hıncal, Novel non-surfactant paclitaxel formulation with amphiphilic β-cyclodextrin nanoparticles: formulation, in vitro evaluation and stability, 2nd EUFEPS/APGI Conference on Optimizing Drug Delivery and Formulation: Evaluation of Drug Delivery Systems: Issues and Perspectives, Versailles, 2005
23. Rouf, A., E. Bilensoy, İ. Vural, A.A. Hıncal, Evaluation of a thermoresponsive gel formulation for clotrimazole-cyclodextrin complex, Pharmaceutical Sciences Fair and Exhibition, Nice, 2005
22. Gürkaynak, O., E. Memişoğu-Bilensoy, M. Ertan ve A.A. Hıncal, 6-O-CAPRO-β-CD: synthesis, characterization and preparation of nanoparticles, 12th International Pharmaceutical Technology Symposium, İstanbul, Alp Ofset, 2004
21. Memişoğlu-Bilensoy, E., Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: system development and evaluation, 6th Central European Symposium on Pharmaceutical Technology and Biotechnology, Siofok, 2005 (invited lecture)
20. Memişoğlu-Bilensoy, E., Bochot, A., Duchene, D., Hıncal, A.A., Tamoxifen citrate loaded amphiphilic b-cyclodextrin nanoparticles, 12th International Symposium on Cyclodextrins, Kluwer, Montpellier, 2004
19. Memişoğlu-Bilensoy, E., Applications of amphiphilic cyclodextrins to drug delivery systems, 11th International Biomedical Science and Technology Days, Ankara, 2004 (invited lecture)
18. Memişoğlu-Bilensoy, E., M. Şen, A. Bochot, D. Duchene, ve A.A. Hıncal, “Effect of Drug Physicochemical properties on In Vitro Behavior of Amphiphilic b-cyclodextrin (b-CDC6) Nanocapsules”, 1st EUFEPS Conference on Optimising Drug Delivery. New Challenges in Drug Delivery, Versailles, 2003
17. Hıncal, A.A., E. Memişoğlu-Bilensoy, S. Çalış, ve F. Hıncal, Critical parameters concerning the design of a pharmaceutical dosage form for potential use against bioterrorism and chemical weapons: an overview on current concepts and future prospects, CBMTS III Industry Workshop, Dubrovnik, 2003
16. Hıncal, A.A. ve E. Memişoğlu-Bilensoy, Evaluation of amphiphilic β-cyclodextrins as novel excipients for nanoparticulate drug delivery systems, 7th ISOPS International Symposium on Pharmaceutical Sciences, Ankara, 2003 (invited lecture)
15. Hıncal, A.A., E. Memişoğlu-Bilensoy, A. Bochot, ve D. Duchene, β-cyclodextrines amphiphiles: evaluation de nouveaux excipients pour la preparation de nanoparticules destinees a l’administration par voie parenterale ou topique, Journées Méditérranéennes Marcel Gattefossé, 2003, Saint Remy de Provence
14. Hıncal, A.A., İ. Vural ve E. Memişoğlu, “Advanced drug delivery systems: current state and future prospects, 3rd Yugoslav Congress of Pharmacy with International Participation-New Horizons in Pharmacy, 2002, Belgrad
13. Memişoğlu, E., A. Bochot, D. Duchene, ve A.A. Hıncal, “Preparation and characterization of progesterone-loaded amphiphilic β-cyclodextrin nanospheres, GPEN Globalization of Pharmaceutics Education Network 2002, 2002, Ann Arbor, ABD (oral presentation)
12. Memişoğlu, E., İ. Vural, D. Güç, L. Doğan ve A.A. Hıncal, Evaluation of in vitro cytotoxicity of amphiphilic b-cyclodextrin nanospheres and nanocapsules on human fibroblast and granulocytes, EUFEPS 2002 Congress on New Safe Medicines Faster, 2002, Stockholm
11. Memişoğlu, E., A. Bochot, D. Duchene ve A.A. Hıncal, Haemolytic evaluation of nanospheres prepared from amphiphilic b-cyclodextrins modified on the primary or secondary face, EUFEPS 2002 Congress on New Safe Medicines Faster, 2002, Stockholm
10. Memişoğlu, E., A. Bochot, M. Özalp, M. Şen, D. Duchene ve A.A. Hıncal, “Highly-Loaded Nanospheres Prepared Directly from Amphiphilic β-CD Inclusion Complexes with Bifonazole and Clotrimazole as Model Drugs”, 11th International Pharmaceutical Technology Symposium, 2002, İstanbul
9. Memişoğlu, E., A. Bochot, D. Charon, D. Duchene, ve A.A. Hıncal, Amphiphilic β-cyclodextrin nanocapsules: preparation, characterization and stability, 3rd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology APGI/APV, 2000, Berlin (Oral presentation)
8. Memişoğlu, E., A. Bochot, D. Charon, A.A. Hıncal, ve D. Duchene, Characterization of Nanocapsules Composed of Amphiphilic Beta-Cyclodextrins Modified on the Primary Face, 6th European Congress of Pharmaceutical Sciences-EUFEPS 2000, 2000, Budapest
7. Memişoğlu, E., A. Bochot, D. Charon, D. Duchene, A.A. Hıncal, Formulation of Novel Amphiphilic Cyclodextrins Modified on the Primary Face in the Form of Nanocapsules, AAPS Millennial World Congress of Pharmaceutical Sciences, 2000, San Francisco
6. Memişoğlu, E., D. Charon, D. Duchene, ve A.A. Hıncal, Synthesis of Per(2,3-di-O-hexanoyl)-b-cyclodextrin and Characterization of Amphiphilic b-cyclodextrin Nanoparticles, 9th International Symposium on Cyclodextrins, 1998, Santiago de Compostela
5. Memişoğlu, E., F. Öner, A. Ayhan, İ. Başaran, H.S. Kaş, ve A.A. Hıncal, Wound Healing Effectiveness of Chitosan Gel Preparations With and Without EGF in a Rabbit Model, 8th International Pharmaceutical Technology Symposium, 1998, Ankara
4. Memişoğlu, E., F. Öner, H.S. Kaş, L. Zarif, A. Ayhan, İ. Başaran, ve A.A. Hıncal, Epidermal Growth Factor EGC wound healing in flurorocarbon and chitosan gels in a rabbit model, 4th International Symposium on Biomedical Science and Technology, 1997, İstanbul
3. Memişoğlu, E., F. Öner, L. Zarif, A. Ayhan, İ. Başaran, H.S. Kaş, ve A.A. Hıncal, Fluorocarbon Based Systems: Wound Healing Potency in Rabbit Model with Epidermal Growth Factor, 4th International Symposium on Biomedical Science and Technology, 1997, İstanbul
2. Memişoğlu, E., F. Öner, İ. Başaran, ve A.A. Hıncal, Wound Healing Effectiveness of rhGM-CSF from Different Topical Formulations, 1st World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 1995, Budapest
1. Memişoğlu, E., F. Öner, M. Yalın, ve A.A. Hıncal, Three Different Vehicle Formulations for the Topical Application of Collagen Chronoprotector Peptide, 7th International Pharmaceutical Technology Symposium, 1994, Ankara